Shayman JA - Search Results

1

Sphingolipids--the enigmatic lipid class: biochemistry, physiology, and pathophysiology.

Merrill AH Jr, Schmelz EM, Dillehay DL, Spiegel S, Shayman JA, Schroeder JJ, Riley RT, Voss KA, Wang E. Merrill AH Jr, et al. Among authors: shayman ja. Toxicol Appl Pharmacol. 1997 Jan;142(1):208-25. doi: 10.1006/taap.1996.8029. Toxicol Appl Pharmacol. 1997. PMID: 9007051 Free article. Review.

2

Sphingolipids.

Shayman JA. Shayman JA. Kidney Int. 2000 Jul;58(1):11-26. doi: 10.1046/j.1523-1755.2000.00136.x. Kidney Int. 2000. PMID: 10886545 Free article. Review.

3

Ceramide 1-phosphate, a mediator of phagocytosis.

Hinkovska-Galcheva V, Boxer LA, Kindzelskii A, Hiraoka M, Abe A, Goparju S, Spiegel S, Petty HR, Shayman JA. Hinkovska-Galcheva V, et al. Among authors: shayman ja. J Biol Chem. 2005 Jul 15;280(28):26612-21. doi: 10.1074/jbc.M501359200. Epub 2005 May 16. J Biol Chem. 2005. PMID: 15899891 Free article.

4

Sphingolipids: their role in intracellular signaling and renal growth.

Shayman JA. Shayman JA. J Am Soc Nephrol. 1996 Feb;7(2):171-82. doi: 10.1681/ASN.V72171. J Am Soc Nephrol. 1996. PMID: 8785385 Review.

5

Establishing a role for sphingolipids in renal injury and stress responses.

Shayman JA. Shayman JA. Kidney Int. 1998 Mar;53(3):790-1. doi: 10.1038/ki.1998.33. Kidney Int. 1998. PMID: 9507228 Free article. No abstract available.

6

Glycosphingolipid depletion in fabry disease lymphoblasts with potent inhibitors of glucosylceramide synthase.

Abe A, Arend LJ, Lee L, Lingwood C, Brady RO, Shayman JA. Abe A, et al. Among authors: shayman ja. Kidney Int. 2000 Feb;57(2):446-54. doi: 10.1046/j.1523-1755.2000.00864.x. Kidney Int. 2000. PMID: 10652021 Free article.

7

Targeting Glucosylceramide Synthesis in the Treatment of Rare and Common Renal Disease.

Shayman JA. Shayman JA. Semin Nephrol. 2018 Mar;38(2):183-192. doi: 10.1016/j.semnephrol.2018.01.007. Semin Nephrol. 2018. PMID: 29602400 Free PMC article. Review.

8

α-galactosidase A deficiency promotes von Willebrand factor secretion in models of Fabry disease.

Kang JJ, Kaissarian NM, Desch KC, Kelly RJ, Shu L, Bodary PF, Shayman JA. Kang JJ, et al. Among authors: shayman ja. Kidney Int. 2019 Jan;95(1):149-159. doi: 10.1016/j.kint.2018.08.033. Epub 2018 Nov 22. Kidney Int. 2019. PMID: 30470436 Free PMC article.

9

The riddle of the sphinx redux.

Shayman JA. Shayman JA. Kidney Int. 2010 May;77(10):843-5. doi: 10.1038/ki.2010.72. Kidney Int. 2010. PMID: 20431574 Free PMC article. Review.

10

Establishing 3-nitrotyrosine as a biomarker for the vasculopathy of Fabry disease.

Shu L, Vivekanandan-Giri A, Pennathur S, Smid BE, Aerts JM, Hollak CE, Shayman JA. Shu L, et al. Among authors: shayman ja. Kidney Int. 2014 Jul;86(1):58-66. doi: 10.1038/ki.2013.520. Epub 2014 Jan 8. Kidney Int. 2014. PMID: 24402087 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

162 results

Search Page